Oregon Public Employees Retirement Fund bought a new stake in ZimVie Inc. (NASDAQ:ZIMV – Get Rating) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 6,894 shares of the company's stock, valued at approximately $68,000.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Monarch Capital Management Inc. acquired a new position in ZimVie in the third quarter valued at approximately $227,000. Hellman Jordan Management Co. Inc. MA acquired a new position in ZimVie in the second quarter valued at approximately $724,000. Douglas Lane & Associates LLC acquired a new position in ZimVie in the third quarter valued at approximately $192,000. Raymond James & Associates acquired a new position in ZimVie in the third quarter valued at approximately $110,000. Finally, Comerica Bank acquired a new position in ZimVie in the third quarter valued at approximately $110,000. 74.29% of the stock is currently owned by institutional investors and hedge funds.
Get ZimVie alerts:Analyst Upgrades and Downgrades
Separately, Barclays assumed coverage on ZimVie in a research note on Wednesday, December 21st. They issued an "underweight" rating and a $9.00 target price for the company.
ZimVie Price Performance
Shares of NASDAQ ZIMV opened at $9.09 on Friday. The company has a current ratio of 2.51, a quick ratio of 1.48 and a debt-to-equity ratio of 0.76. The stock has a 50 day simple moving average of $8.95 and a 200-day simple moving average of $11.74. ZimVie Inc. has a 12-month low of $6.67 and a 12-month high of $50.40.ZimVie (NASDAQ:ZIMV – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.22. The business had revenue of $214.58 million during the quarter, compared to the consensus estimate of $214.83 million. ZimVie had a negative return on equity of 2.75% and a negative net margin of 9.96%. On average, equities analysts expect that ZimVie Inc. will post 1.95 earnings per share for the current year.
About ZimVie
(Get Rating)
ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.
Recommended Stories
- Get a free copy of the StockNews.com research report on ZimVie (ZIMV)
- MarketBeat Week in Review – 1/23- 1/27
- Why Lucid Spiked Nearly 100% In One Day
- Ride These Railroad Stocks for Growth and Income
- ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
- KLA Corporation: Strength In A Troubled Semi-Market
Want to see what other hedge funds are holding ZIMV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ZimVie Inc. (NASDAQ:ZIMV – Get Rating).
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.